Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

BioDrive, Inc.

Has BioDrive, Inc. received an FDA warning letter? Yes. FDA issued a warning letter dated August 24, 2026.

Letter facts

Letter date
August 24, 2026 (2026-08-24)
Issuing office
Human Foods Program
Products named
Evolv GLP-1 Biomimetic dietary supplement
Violation categories
Other

Understanding these violation categories

Other

FDA cited violations of federal regulations governing drug research, clinical trials, or product distribution. A warning letter is an advisory notice allowing the recipient to respond.

Factual Violation Summary

FDA says Evolv GLP-1 Biomimetic contains EV1-Peptide, a new dietary ingredient with inadequate safety information and potential toxicity concerns; FDA deemed it adulterated under section 402(f)(1)(B) despite two NDIN objections.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Adulterated dietary supplement
  • New dietary ingredient (NDI) without adequate safety information
  • Introduction of adulterated product into interstate commerce

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Other)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.